IDARUBICIN HYDROCHLORIDE (IDAMYCIN)

Course overview

IDArubicin is U.S. FDA-approved to treat acute myeloid leukemia (AML) in adults, in combination with other antileukemic agents. It must be used cautiously in older patients, and in patients with preexisting cardiac disease, prior radiotherapy, liver disease, or renal disease. This continuing education module is designed to give the reader/learner an increased understanding of idarubicin. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.